Immunofluorescence and western blot analysis confirmed reduced MMP‐2 and MMP‐9 protein expression and an increased Bax/Bcl‐2 ratio following emodin treatment, which indicates emodin's potential as a therapeutic option for highly metastatic melanoma [112]. Here, MMP9 is linked to melanoma.